Similarly, IL-1β inhibitors such as Anakinra, Rilonacept, Gevokizumab or Canakinumab [31] and selective NLRP3 inflammasome inhibitors [32] may be useful for PAD patients with TET2 loss-of-function mutations [2,20,27]. This evidence concerns the gene TET2 and peripheral arterial disease.